Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MRNA - Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

MRNA - Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Moderna Inc.
  • Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma.
  • AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.
  • The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
  • Patent dispute ongoing over Moderna's Covid-19 Vaccine. Favorable ruling in favor of Arbutus from Federal Appeals Court would be huge news for the company as it relates to its patents for lipid nanoparticles.

For further details see:

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Stock Information
Company Name: Moderna Inc.
Stock Symbol: MRNA
Market: NASDAQ
Website: modernatx.com
Menu
MRNA MRNA Quote MRNA Short MRNA News MRNA Articles MRNA Message Board
Get MRNA Alerts

News, Short Squeeze, Breakout and More Instantly...